Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with <i>METex14</i> skipping alterations: post-marketing surveillance in Japan
Tepotinib was generally well tolerated and effective in patients with NSCLC and METex14 skipping alterations in general clinical practice in Japan; no new safety issues or concerns were identified.
Authors
- Masashi Sato (ORCID: https://orcid.org/0009-0009-3852-4591)
- Risa Kojima
- Terufumi Kato (ORCID: https://orcid.org/0000-0002-5853-1424)
- Eisuke Horii
- Kazuhiko Nakagawa (ORCID: https://orcid.org/0000-0003-1284-9776)
- Tatsuya Ogura (ORCID: https://orcid.org/0000-0002-6254-2337)
- Bingbing Song
Institutions
- Merck KGaA, Darmstadt (Germany) (DE)
- Kanagawa Prefectural Hospital Organization (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Kindai University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1093/jjco/hyaf099
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck KGaA